APR-26-11 On April 27 and 28, the FDA's Antiviral Drugs Advisory Committee will meet to discuss new drug applications for the first in class HCV protease inhibitors, Boceprevir (April 27) and Telaprevir (April 28).

Materials Now Available Here

Materials now available by clicking or following: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/ucm247236.htm